BR112016029201B8 - Quimera de ácido nucleico, composição imunogênica, uso de um ou mais vírus inativados compreendendo a quimera de ácido nucleico e método para inativar um vírus - Google Patents

Quimera de ácido nucleico, composição imunogênica, uso de um ou mais vírus inativados compreendendo a quimera de ácido nucleico e método para inativar um vírus

Info

Publication number
BR112016029201B8
BR112016029201B8 BR112016029201A BR112016029201A BR112016029201B8 BR 112016029201 B8 BR112016029201 B8 BR 112016029201B8 BR 112016029201 A BR112016029201 A BR 112016029201A BR 112016029201 A BR112016029201 A BR 112016029201A BR 112016029201 B8 BR112016029201 B8 BR 112016029201B8
Authority
BR
Brazil
Prior art keywords
nucleic acid
chimera
serotype
denv
acid chimera
Prior art date
Application number
BR112016029201A
Other languages
English (en)
Other versions
BR112016029201B1 (pt
BR112016029201A2 (pt
Inventor
Y H Kinney Claire
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of BR112016029201A2 publication Critical patent/BR112016029201A2/pt
Publication of BR112016029201B1 publication Critical patent/BR112016029201B1/pt
Publication of BR112016029201B8 publication Critical patent/BR112016029201B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

vírus do oeste do nilo/dengue quiméricos e métodos de uso. estão descritos aqui flavivírus quiméricos que incluem regiões não codificadoras, proteínas não estruturais e pelo menos uma porção de uma proteína c do vírus nilo (wnv) e uma proteína prm e uma proteína e do vírus da dengue (denv). o denv pode ser do sorotipo den1, sorotipo den2, sorotipo den3 ou sorotipo den4. também estão descritas aqui composições e métodos para desencadear uma resposta imune em um indivíduo tal como uma resposta imune a um ou mais sorotipos de denv. em modalidades particulares, as composições incluem um ou mais vírus inativados que incluem um ácido nucleico quimérico de wn/denv (tal como uma vacina inativada tetravalente que inclui uma quimera de wn/den1, uma quimera de wn/den2, uma quimera de wn/den3 e uma quimera de wn/den4). as composições podem ser administradas a um indivíduo para desencadear uma resposta imune.
BR112016029201A 2014-06-20 2015-06-19 Quimera de ácido nucleico, composição imunogênica, uso de um ou mais vírus inativados compreendendo a quimera de ácido nucleico e método para inativar um vírus BR112016029201B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462015265P 2014-06-20 2014-06-20
US62/015,265 2014-06-20
PCT/US2015/036728 WO2015196094A1 (en) 2014-06-20 2015-06-19 Chimeric west nile/dengue viruses and methods of use

Publications (3)

Publication Number Publication Date
BR112016029201A2 BR112016029201A2 (pt) 2017-10-17
BR112016029201B1 BR112016029201B1 (pt) 2023-11-14
BR112016029201B8 true BR112016029201B8 (pt) 2023-12-05

Family

ID=53524961

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016029201A BR112016029201B8 (pt) 2014-06-20 2015-06-19 Quimera de ácido nucleico, composição imunogênica, uso de um ou mais vírus inativados compreendendo a quimera de ácido nucleico e método para inativar um vírus

Country Status (6)

Country Link
US (1) US10428313B2 (pt)
EP (1) EP3158061B1 (pt)
CN (1) CN106574271B (pt)
AU (1) AU2015276929B2 (pt)
BR (1) BR112016029201B8 (pt)
WO (1) WO2015196094A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3030154A1 (en) 2016-07-08 2018-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric dengue/zika viruses live-attenuated zika virus vaccines
US10632185B2 (en) 2016-07-08 2020-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric west nile/zika viruses and methods of use
WO2019036617A1 (en) 2017-08-18 2019-02-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services DENGUE / WESTERN NILE VIRUSES OF GENETIC RAPPORTEUR GENES, AND USE THEREOF

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939254A (en) 1997-04-28 1999-08-17 University Of Massachusetts Methods and reagents for rapid diagnosis of dengue virus infection
US6793488B1 (en) 1999-04-16 2004-09-21 U.S. Army Medical Research & Materiel Command Flavivirus detection and quantification assay
ES2374131T3 (es) * 2000-02-16 2012-02-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Flavivirus quiméricos avirulentos e inmunógenos.
EP1401859B1 (en) * 2001-06-01 2013-08-07 Sanofi Pasteur Biologics Co. Chimeric flavivirus vectors
AU2003205169A1 (en) 2002-01-15 2003-07-30 Acambis, Inc. Viral vaccine production method
US8124397B2 (en) 2005-08-08 2012-02-28 Oregon Health & Science University Inactivating pathogens with oxidizing agents for vaccine production
US8815564B2 (en) * 2008-03-14 2014-08-26 Sanofi Pasteur Biologics, Llc Replication-defective flavivirus vaccines and vaccine vectors
US8715689B2 (en) 2008-04-30 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric west nile/dengue viruses

Also Published As

Publication number Publication date
BR112016029201B1 (pt) 2023-11-14
EP3158061B1 (en) 2019-08-07
CN106574271B (zh) 2020-06-16
WO2015196094A1 (en) 2015-12-23
EP3158061A1 (en) 2017-04-26
CN106574271A (zh) 2017-04-19
US10428313B2 (en) 2019-10-01
AU2015276929A1 (en) 2016-12-22
BR112016029201A2 (pt) 2017-10-17
AU2015276929B2 (en) 2021-04-08
US20170114330A1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
BR112018013387A2 (pt) vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit
BR112018009032A2 (pt) vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, método para o tratamento ou a prevenção de infecção pelo vírus da hepatite b em um paciente, uso de um vetor viral, ácido nucleico isolado, vetor viral de arenavírus infeccioso deficiente em replicação e método para sua geração
CO2018006706A2 (es) Virus mutados, método de preparación y uso de los mismos
UY35131A (es) Composiciones, métodos y usos de construcciones de virus del dengue de serotipo-4
CO2018010874A2 (es) Vacuna de virus de zika atenuado vivo
BR112018071087A2 (pt) composições e métodos de vacinação contra o vírus da dengue em crianças e adultos jovens
BR112018077540A2 (pt) vírus quimérico da dengue/zika como vacinas de zika vírus vivo atenuado
HRP20100314T1 (hr) Cjepivo protiv nipah virusa
MX2016003419A (es) Metodos y composiciones para sindrome respiratorio coronavirus de oriente medio (mers-cov) inmunogenico.
JP2015524421A5 (pt)
CL2020001428A1 (es) Terapia genética para la mucopolisacaridosis iiib.
PH12015502120A1 (en) Compositions and methods for dengue virus chimeric constructs in vaccines
CU20110219A7 (es) Composiciones y métodos para administración de vacunas contra virus del dengue
PH12020550266A1 (en) Stable vaccine compositions comprising inter alia live attenuated recombinant flavivirus and process for preparation thereof
BR112016029201B8 (pt) Quimera de ácido nucleico, composição imunogênica, uso de um ou mais vírus inativados compreendendo a quimera de ácido nucleico e método para inativar um vírus
CO6440541A2 (es) Virus de diarrea viral bovina con una proteina erns modificada
AR101814A1 (es) Partícula de tipo virus flavivirus
AR100608A1 (es) Complejos de citomegalovirus y usos de los mismos
CR20140189S (es) Vacunas y metodos para crear una vacuna para inducir la inmunidad a todos los serotipos del virus del dengue
GEP20237539B (en) Formulations of dengue virus vaccine compositions
WO2012065105A3 (en) Chimeric flavivirus vaccines
BR112018069079A2 (pt) construtos de alfavírus vivos atenuados e métodos e usos dos mesmos
PH12020550569A1 (en) A zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
MX2020006476A (es) Vacuna contra el virus de lassa.
WO2016130786A3 (en) Flaviviridae proteins and virions and methods of use thereof

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/06/2015, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2758 DE14/11/2023, QUANTO AO ITEM (54) TITULO.